NKTX earnings analysis
What we found in NKTX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Nkarta remains a clinical-stage company with no disclosed product revenue, and second-quarter diluted EPS of negative $0.54 was worse than both the prior quarter’s negative $0.37 and the prior-year quarter’s negative $0.31. The company retains substantial liquidity of $243.2 million and expects its current plan to be funded into 2029, while R&D spending rose 20% year over year to $54.0 million for the first six months. Protocol amendments for outpatient dosing, re-dosing and an RA cohort expand the NKX019 opportunity but also increase execution, safety, enrollment and manufacturing risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Quarterly Loss Deepened
- Second-quarter diluted EPS was a loss of $0.54, worsening from a $0.37 loss in 2026 Q1 and a $0.31 loss in 2025 Q2.
- Cash Runway Extends Into 2029
- Cash, cash equivalents, restricted cash and investments totaled $243.2 million as of June 30, 2026, with management expecting funding into 2029.
- R&D Spending Increased 20%
- Research and development expense increased to $54.0 million for the six months ended June 30, 2026, from $45.0 million in the comparable 2025 period, a $9.0 million or 20% increase.
- NKX019 Trial Protocol Expanded
- FDA-agreed protocol amendments support outpatient NKX019 administration, potential re-dosing, an RA cohort in Ntrust-2 and removal of geographic monitoring requirements; the amended protocols reduce post-dose monitoring from 24 hours to 2 hours.
- Organization Supports Clinical Programs
- Nkarta had 106 full-time employees as of June 30, 2026, supporting continued clinical development and manufacturing activities.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Large and Continuing Operating Losses
- The amended risk factor states that net losses were $68.2 million for the six months ended June 30, 2026, while accumulated deficit reached $716.5 million; management expects increasing operating losses as NKX019 development continues.
- Additional Financing May Be Required
- The company states that advancing NKX019 or another product candidate into pivotal trials will require additional capital. As of June 30, 2026, cash, cash equivalents, restricted cash and investments were $243.2 million, and future equity financing could dilute existing holders.
- Clinical Enrollment Remains Challenging
- Enrollment remains a material risk across the two Phase 1/2 autoimmune studies, Ntrust-1 and Ntrust-2, which cover six named autoimmune indications: lupus nephritis, pMN, scleroderma, myositis, AAV and RA. The filing states that the company has had significant enrollment challenges and may continue to experience them.
- Outpatient and Re-Dosing Safety Risk
- Moving to outpatient dosing reduces required monitoring from 24 hours to 2 hours, while safety at higher dose levels remains under evaluation. The filing also identifies additional safety risks from re-dosing, including cumulative toxicity and immunogenicity.
- Manufacturing Asset Impairment Risk
- The filing identifies a newly highlighted impairment risk after the company decided during the quarter ended June 30, 2026 to sublease part of its facility and stop using certain equipment, resulting in impairment charges during the quarter.
- Ownership and Share-Sale Overhang
- As of August 5, 2026, directors, executive officers and holders of more than 5% of the company’s stock beneficially owned 37% of common stock, while 8,417,761 shares had registration rights and 74,624,822 shares were outstanding including pre-funded warrants, creating potential governance and selling-pressure risks.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.54
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management previously stated that cash and cash equivalents of $243.2 million were expected to fund the current operating plan into 2029; explicit quantitative outlook was otherwise deferred to the earnings release/call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 12, 2026
- Nkarta, Inc. reported a first-quarter loss of $27.8 million and a diluted EPS of -$0.37, missing consensus EPS estimates of -$0.30. Although the company is still pre-revenue with no product sales, its cash and…
- 10-K · March 25, 2026
- Nkarta is a clinical-stage company focused on an allogeneic CAR NK platform with lead program NKX019 (CD19) being evaluated in multiple Phase 1 trials for autoimmune diseases (Ntrust-1, Ntrust-2 and several ISTs). The…
- 10-Q · November 10, 2025
- Nkarta, Inc. reported no product revenue for Q3 2025, continuing its trend of financial losses with a net loss of $21.7 million compared to $28.3 million in Q3 2024. The company showed a slight improvement in EPS,…
- 10-Q · August 12, 2025
- Nkarta reported no product revenue and a continuing net loss but showed modest operating expense reductions and an EPS improvement. Q2 results include net loss per share of $(0.31) (vs $(0.34) in Q2 2024) and total…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NKTX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever